SotiriosTsimikasMD

Interventional Cardiology

Professor, Medicine, UCSD School of Medicine

Dr. Tsimikas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 W Arbor Dr
San Diego, CA 92103
Phone+1 858-657-8530

Fax+1 858-657-8021

University of California (San Diego) Medical CenterFellowship, Cardiovascular Disease, 1992 - 1996
UMass Chan Medical SchoolResidency, Internal Medicine, 1988 - 1991
University of Massachusetts Medical SchoolClass of 1988

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Fellow (FACC) American College of Cardiology

PubMed

Polygenic risk, aspirin, and primary prevention of coronary artery disease.
Chenglong Yu, Pradeep Natarajan, Aniruddh P Patel, Harpreet S Bhatia, Amit V Khera
European Heart Journal. Cardiovascular Pharmacotherapy. 2025-02-08
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.
Harpreet S Bhatia, Simon Wandel, Peter Willeit, Anastasia Lesogor, Keith Bailey
Circulation. 2025-01-28
Differential effects of volanesorsen on apoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or non-genetic criteria.
Sotirios Tsimikas, Henry N Ginsberg, Veronica J Alexander, Ewa Karwatowska-Prokopczuk, Andy Dibble
Journal of Clinical Lipidology. 2024-12-21

Journal Articles

Lipoprotein(A) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas, MD, The New England Journal of Medicine
Lipoprotein(A) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas, MD, The New England Journal of Medicine
Lipoprotein(A) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas, MD, The New England Journal of Medicine
Publisher Correction: Oxidized Phospholipids Are Proinflammatory and Proatherogenic in Hypercholesterolaemic Mice
Kirk L Peterson, Sotirios Tsimikas, Thomas A Prohaska, Nature
Oxidized Phospholipids Are Proinflammatory and Proatherogenic in Hypercholesterolaemic Mice
Sotirios Tsimikas, Kirk L Peterson, Thomas A Prohaska, Nature
Join now to see all

The Role of Lipoprotein(A) in Calcific AV Disease and Insights into Its Medical TherapiesApril 2020
The Role of Lipoprotein(A) in Calcific AV Disease and Insights into Its Medical TherapiesApril 2020
Lipoprotein(A) Reduction in Persons with Cardiovascular DiseaseJanuary 2020
PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes with a Human Antibody Detects Clinically Relevant AtherothrombosisJanuary 2018
Join now to see all

JACC - Oxidized Phospholipids and Calcific Aortic Valvular DiseaseNovember 20th, 2024
High Lp(A) Linked to ASCVD Risk Even When LDL Cholesterol Is LowNovember 13th, 2024
Lp(A) Packs a More Powerful Atherogenic Punch Than LDLJanuary 29th, 2024
Join now to see all